These differences in the mode of action might provide a rationale for our observation of a gap junction targeted therapy to synergize for lomustine-induced cytotoxic effects in both MGMT promoter methylated and unmethylated glioblastoma cells. The gene discussed is MGMT; the disease is glioblastoma.